What question did this study set out to answer?

To develop an efficient method for differentiating cardiac stromal cells from human pluripotent stem cells without using animal serum.

June 18, 2026Scientific ReportsOpen Access

Efficient multi-lineage cardiovascular differentiation of human pluripotent stem cells in animal serum-free conditions

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates serum substitutes in generating functional engineered heart tissue, indicating potential alternatives to animal serum.

To develop an efficient method for differentiating cardiac stromal cells from human pluripotent stem cells without using animal serum.
Utilized Panexin as a serum substitute for differentiation of cardiac stromal lineages with 85% purity.
Evaluated fabrication of engineered heart tissues using hiPSC-cardiomyocytes in monoculture and with cardiac fibroblasts and endothelial cells in triculture.
Assessed the impact of TGFβ inhibition on cardiac myofibroblast activation during EHT fabrication.
Panexin supported differentiation to 85% purity but poorly enabled engineered heart tissue (EHT) fabrication and contractility.
Mono- and tri-culture EHTs fabricated with human serum exhibited stronger contractile forces compared to those made with animal serum.
Inhibition of TGFβ signalling did not improve EHT contractility, highlighting its significance in achieving optimal performance.

Vo et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial evaluates serum substitutes in generating functional engineered heart tissue, indicating potential alternatives to animal serum.